Der diagnostische Stellenwert der Isocitrat-Dehydrogenase-Mutationen beim Chondrosarkom

Im Jahre 2008 wurden erstmalig durch Parsons et al. bei einer kleinen Gruppe von jungen Gliompatienten somatische Mutationen in dem Gen für das Enzym Isocitrat-Dehydrogenase IDH1 (Chromosom 2q33) entdeckt [1]. Wenig später folgte der Nachweis der IDH1-Mutation bei dem zentralen Chondrosarkom durch Amary und Kollegen [2].

Publikationsverlauf

Artikel online veröffentlicht:
21. Februar 2022

• 1 Parsons DW, Jones S, Zhang X. et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321: 1807-1812 1164382 [pii]
• 2 Amary MF, Bacsi K, Maggiani F. et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 2011; 224: 334-343
• 3 Geisbrecht BV, Gould SJ. The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase.. J Biol Chem 1999; 274: 30527-30533
• 4 Yoshihara T, Hamamoto T, Munakata R, Tajiri R, Ohsumi M, Yokota S. Localization of cytosolic NADP-dependent isocitrate dehydrogenase in the peroxisomes of rat liver cells: biochemical and immunocytochemical studies. J Histochem Cytochem. 2001; 49: 1123-1131
• 5 Bleeker FE, Atai NA, Lamba S. et al. The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol 2010; 119: 487-494
• 6 Mailloux RJ, Bériault R, Lemire J. et al. The tricarboxylic acid cycle, an ancient metabolic network with a novel twist. PLoS One 2007; 2: e690
• 7 Dang L, White DW, Gross S. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009; 462: 739-744 08617 [pii]
• 8 Juratli TA, Peitzsch M, Geiger K, Schackert G, Eisenhofer G, Krex D. Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas. Neuro Oncol 2013; 15: 682-690
• 9 Jin G, Reitman ZJ, Duncan CG. et al. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Res. 2013; 73: 496-501
• 10 Xu W, Yang H, Liu Y. et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell 2011; 19: 17-30 S1535-6108(10)00527-1 [pii]
• 11 Ward PS, Cross JR, Lu C. et al. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogene 2012; 31: 2491-2498
• 12 Gross S, Cairns RA, Minden MD. et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010; 207: 339-344 jem.20092506 [pii]
• 13 Honey EM, van Rensburg M, Knoll DP, Mienie LJ, van de Werke I, Beighton P. Spondyloenchondromatosis with D-2-hydroxyglutaric aciduria: a report of a second patient with this unusual combination. Clin Dysmorphol. 2003; 12: 95-99
• 14 Talkhani IS, Saklatvala J, Dwyer J. D-2-hydroxyglutaric aciduria in association with spondyloenchondromatosis. Skeletal Radiol 2000; 29: 289-292
• 15 Pansuriya TC, van Eijk R, d'Adamo P. et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 2011; 43: 1256-1261
• 16 Amary MF, Damato S, Halai D. et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet 2011; 43: 1262-1265
• 17 Yang H, Ye D, Guan KL, Xiong Y. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin Cancer Res 2012; 18: 5562-5571
• 18 Choi JH, Ro JY. The 2020 WHO Classification of Tumors of Bone: An Updated Review. Adv Anat Pathol 2021; 28: 119-138
• 19 Zhu GG, Nafa K, Agaram N. et al. Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma. Clin Cancer Res 2020; 26: 419-427
• 20 Pope WB, Prins RM, Albert Thomas M. et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol 2012; 107: 197-205